Close Menu

NEW YORK – In the early days of the coronavirus pandemic, pooled molecular testing for SARS-CoV-2 was promoted as an approach that could increase lab capacity while saving valuable resources such as reagents and other supplies.

But as COVID-19 positivity rates have reached new highs and because of the logistical and personnel challenges involved in running pooled testing, implementation of the method has been limited, especially within smaller facilities, said a number of laboratory heads.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.